HGH Fragment 176-191

Fitness

Also known as: HGH Frag, hGH Frag 176-191, GH Fragment 176-191, Lipolytic Fragment

Unproven

What is HGH Fragment 176-191?

The unmodified C-terminal fragment (amino acids 176-191) of human growth hormone, isolated by researchers at Monash University in the 1990s to capture GH's fat-burning effect without its growth-promoting or blood-sugar-raising effects. It is the direct predecessor of AOD-9604, the stabilized version that was actually taken into human clinical trials — and that distinction matters more than almost anything else about this peptide, because most of the "evidence" cited for HGH Frag 176-191 online is really AOD-9604 or animal data.

How it works

Full-length growth hormone has several separable functional regions: a receptor-binding domain that drives growth and IGF-1 production, an insulin-antagonist region linked to GH's diabetogenic effects, and a C-terminal lipolytic region. Ng and colleagues showed that isolating just the 176-191 fragment retained GH's ability to stimulate lipolysis (via beta-3 adrenergic receptor activation and hormone-sensitive lipase) and suppress lipogenesis (via fatty acid synthase inhibition) in adipose tissue, without triggering the growth-promoting or insulin-resistance effects tied to the rest of the molecule. The problem is that the unmodified 16-amino-acid fragment is structurally unstable and prone to rapid degradation and oxidation. That instability is exactly why Metabolic Pharmaceuticals developed AOD-9604 — a version with a modified, capped end designed to resist degradation — and moved that stabilized molecule into human trials rather than the original fragment.

What marketers claim

▸targeted fat-burning without affecting blood sugar or growth
▸clinically proven based on human trial data
▸safe, natural alternative to full HGH for fat loss
▸burns stubborn fat when combined with fasted cardio
▸no side effects since it is just a fragment of a natural hormone

What evidence supports

✓the 176-191 region is genuinely the lipolytic domain of GH, identified through legitimate research at Monash University in the 1990s
✓in rat adipocyte and mouse obesity (ob/ob) studies, the fragment stimulated lipolysis and reduced fat mass without the glucose or IGF-1 effects seen with full GH
✓effects in beta-3 adrenergic receptor knockout mice were abolished, supporting a specific, identifiable mechanism rather than a generic hormonal effect
✓the stabilized derivative, AOD-9604, was tested in actual human trials — but that data belongs to AOD-9604, not to this unmodified fragment

Best for

understanding how a legitimate discovery (the lipolytic domain of GH) got separated from its actual clinical evidence (which belongs to AOD-9604) as it moved into grey-market sales

Safety notes & concerns

Full safety guide →

⚠the unmodified fragment has not been studied in humans — nearly every human-relevant claim made about it is actually AOD-9604 trial data or animal-model data being extrapolated onto a different (less stable) molecule
⚠AOD-9604 itself, despite being the properly-trialed, stabilized version, failed to beat placebo for weight loss in its pivotal Phase IIb trial (536 subjects), and the developer discontinued the obesity program in 2007
⚠the raw 176-191 fragment is chemically less stable than AOD-9604 — it is more prone to degradation, which raises real questions about the potency and consistency of grey-market vials sold under this name
⚠no published human pharmacokinetic or safety data exists for the unmodified fragment specifically, so dosing protocols circulating online are not derived from any clinical study
⚠sold almost exclusively as an unregulated "research chemical," with no oversight of purity, concentration, or sterility
⚠user reports across peptide communities skew toward no noticeable fat-loss effect, consistent with the thin evidence base rather than the marketing claims

Pairs well with

nothing — there is no clinical protocol for this specific molecule to pair with

Use caution with

treating this as interchangeable with AOD-9604 trial results — it is a different, less stable molecule with no human data of its ownexpecting meaningful fat loss — even the clinically-trialed, more stable version failed its pivotal human trialself-sourcing from unregulated research-chemical vendors for injectionconsult a physician before using any unregulated injectable peptide

Frequently asked questions

Is HGH Fragment 176-191 the same as AOD-9604?

No, though they are closely related and often confused. HGH Fragment 176-191 is the original, unmodified 16-amino-acid piece of human growth hormone identified by Monash University researchers. AOD-9604 is a further-modified, more chemically stable version of that same fragment, engineered specifically because the unmodified fragment degrades too easily to be a reliable drug candidate. AOD-9604, not the unmodified fragment, is the one that went into human clinical trials.

Does the human trial data for AOD-9604 apply to HGH Fragment 176-191?

Not directly. This is the single most important thing to understand about this peptide: the unmodified 176-191 fragment has not been studied in humans. Wikipedia's own entry on it notes it "has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604." Any claim you see that treats human AOD-9604 trial results as proof this fragment works is making an unsupported leap between two different molecules.

Did AOD-9604 even work in its human trials?

Not convincingly. An earlier, smaller trial showed a modest weight-loss signal versus placebo, but the pivotal, adequately powered Phase IIb trial (536 obese subjects, 24 weeks) failed to show statistically significant weight loss at any tested dose. Metabolic Pharmaceuticals discontinued the obesity development program in 2007. So even setting aside the fragment-vs-AOD-9604 confusion, the closest thing to real human evidence for this fat-burning mechanism did not hold up in its most rigorous test.

Is HGH Fragment 176-191 dangerous?

There is no published human safety or pharmacokinetic data on the unmodified fragment specifically, so a clear risk profile does not exist. The animal data and the limited AOD-9604 human data did not flag the growth-promoting or blood-sugar effects seen with full GH, which is a genuinely encouraging mechanistic finding. But that reassurance comes from a different, more stable molecule and from animal models — it should not be read as a safety guarantee for an unregulated, unstable research-chemical version sold for self-injection.

Why do sellers dose it at 250-500 mcg per day if there is no human data?

Those protocols are not derived from any published clinical study of this fragment — there isn't one. They appear to be extrapolated from AOD-9604 dosing ranges and general research-peptide community convention, not from dose-finding trials on the unmodified molecule itself.

Related fitness peptides

CJC-1295

those exploring growth hormone optimization under medical supervision

Limited Evidence

Ipamorelin

investigational GH axis optimisation in adults seeking to restore youthful GH pulsatility for recovery, sleep quality, and body composition — in a research context with physician oversight; Sermorelin is the more legally accessible clinical alternative in the US for similar goals

Emerging Research

MK-677 (Ibutamoren)

understanding GH secretagogue research — use under medical supervision only

Well-Studied

GHRP-6

research context — those exploring GH secretagogues under medical supervision

Well-Studied